Bioterinity.jpg

BioTrinity 2014 – European Biopartnering and Investment Conference

BioTrinity 2014 – European Biopartnering and Investment Conference

Take this opportunity to meet  the key licensing contacts from big pharma including  AbbVie, Amgen, AstraZeneca, Boehringer, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GE, GSK, Ipsen, J&J, Janssen R&D, Linde Healthcare, MSD, Novartis, Novo Nordisk, Shire, Pfizer, Takeda, Teijin, UCB, Vertex, Genus, EUSA, Nordic Pharma, Mercury and many others.

This is an opportunity to meet 100 delegates from active VC and Corporate Venture firms including such as MedImmune Ventures, SR One, Shire Strategic Investment, AbbVie Biotech Ventures, Mitsui & Co., MPHVM, Norgine Investment Fund, Novartis Venture Fund, Takeda Ventures, Boehringer Ingelheim Ventures, Inventages, Amorepacific Ventures, Syncona, Index, Sofinnova and many international VCs.

If you register via the Enterprise Europe Network before March 31 2014, your company gets a reduced registration fee.

When:
May 12-14, 2014
Where: London, UK
Web:
http://www.biotrinity.com/silverstripe/

Contact:  Peter Bäckström, Uminova Innovation/Enterprise Europe Network
peter.backstrom@uminovainnovation.se
090 -15 48 79